Interleukin-18 as a Biomarker for Metabolic Syndrome
Author Information
Author(s): Yamaoka-Tojo Minako, Tojo Taiki, Wakaume Kazuki, Kameda Ryo, Nemoto Shinji, Takahira Naonobu, Masuda Takashi, Izumi Tohru
Primary Institution: Kitasato University
Hypothesis
Circulating levels of IL-18 may enhance atherosclerosis-prone conditions in patients with metabolic syndrome.
Conclusion
IL-18 may be a useful biomarker of the clinical manifestations of metabolic syndrome and for managing cardiovascular risk factors.
Supporting Evidence
- Increased levels of IL-18 were observed more frequently in patients with metabolic syndrome than in pre-metabolic syndrome subjects.
- Weight loss of at least 5% significantly reduced IL-18 levels.
- IL-18 levels were positively associated with waist circumference.
- 89% of subjects achieved significant reductions in weight after lifestyle modifications.
Takeaway
This study found that a protein called IL-18 can help doctors tell if someone has a condition called metabolic syndrome, which can lead to heart problems. Losing weight can lower IL-18 levels and improve health.
Methodology
The study measured circulating IL-18 levels in patients with metabolic syndrome and pre-metabolic syndrome before and after lifestyle modifications.
Limitations
The study cohort was small, which may limit the generalizability of the findings.
Participant Demographics
The study included 78 Japanese outpatients with abdominal obesity, with an average age of 55.4 years.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website